Global Dendritic Cell Cancer Vaccines Market Research Report 2023

Dendritic Cell Cancer Vaccines Market

Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals.

Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dendritic Cell Cancer Vaccines market research.

Among all the currently available immunotherapy strategies, dendritic cell vaccines are the most potent antigen-presenting cells for the effective proliferation of T-cells. The specificity of the treatment has boosted its range of applications and is also witnessing global acceptance. As a result, several companies are collaborating to introduce a novel product. For instance, in March 2022, BioNTech signed into a collaboration with Medigene by which Medigene received USD 29 million as an upfront research fund for the co-development of immunotherapies focusing on multiple types of carcinoma. Further, BioNTech will utilize Medigene’s discovery platform and successfully acquire a preclinical asset. Immunotherapy has great potential for treating minimal residual disease (MRD) by the use of dendritic cells and many studies have yielded promising results with no signs of recurrence of tumor growth. For instance, in May 2022, researchers of the AML-VACCiN consortium, clinically developed a dendritic cell vaccine- DCP-001, so as to vaccinate patients with acute myeloid leukemia to eradicate MRD and to effectively reduce the risk of a relapse. The vaccine candidate is designated as an orphan medicinal product in the EU after reliable results from trial phases I & II.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Dendritic Cell Cancer Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Dendritic Cell Cancer Vaccines Market Report

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Dendritic Cell Cancer Vaccines Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 CreaVax

1.2.3 Sipuleucel-T (Provenge)

1.2.4 Others

1.3 Market by Application

1.3.1 Global Dendritic Cell Cancer Vaccines Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Pediatrics

1.3.3 Adults

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Dendritic Cell Cancer Vaccines Market Perspective (2018-2029)

2.2 Dendritic Cell Cancer Vaccines Growth Trends by Region

2.2.1 Global Dendritic Cell Cancer Vaccines Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Dendritic Cell Cancer Vaccines Historic Market Size by Region (2018-2023)

2.2.3 Dendritic Cell Cancer Vaccines Forecasted Market Size by Region (2024-2029)

2.3 Dendritic Cell Cancer Vaccines Market Dynamics

2.3.1 Dendritic Cell Cancer Vaccines Industry Trends

2.3.2 Dendritic Cell Cancer Vaccines Market Drivers

2.3.3 Dendritic Cell Cancer Vaccines Market Challenges

2.3.4 Dendritic Cell Cancer Vaccines Market Restraints

3.1 Global Top Dendritic Cell Cancer Vaccines Players by Revenue

3.1.1 Global Top Dendritic Cell Cancer Vaccines Players by Revenue (2018-2023)

3.1.2 Global Dendritic Cell Cancer Vaccines Revenue Market Share by Players (2018-2023)

3.2 Global Dendritic Cell Cancer Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Dendritic Cell Cancer Vaccines Revenue

3.4 Global Dendritic Cell Cancer Vaccines Market Concentration Ratio

3.4.1 Global Dendritic Cell Cancer Vaccines Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Dendritic Cell Cancer Vaccines Revenue in 2022

3.5 Dendritic Cell Cancer Vaccines Key Players Head office and Area Served

3.6 Key Players Dendritic Cell Cancer Vaccines Product Solution and Service

3.7 Date of Enter into Dendritic Cell Cancer Vaccines Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Dendritic Cell Cancer Vaccines Historic Market Size by Type (2018-2023)

4.2 Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Type (2024-2029)

5.1 Global Dendritic Cell Cancer Vaccines Historic Market Size by Application (2018-2023)

5.2 Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Application (2024-2029)

6.1 North America Dendritic Cell Cancer Vaccines Market Size (2018-2029)

6.2 North America Dendritic Cell Cancer Vaccines Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023)

6.4 North America Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Dendritic Cell Cancer Vaccines Market Size (2018-2029)

7.2 Europe Dendritic Cell Cancer Vaccines Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023)

7.4 Europe Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Dendritic Cell Cancer Vaccines Market Size (2018-2029)

8.2 Asia-Pacific Dendritic Cell Cancer Vaccines Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Dendritic Cell Cancer Vaccines Market Size by Region (2018-2023)

8.4 Asia-Pacific Dendritic Cell Cancer Vaccines Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Dendritic Cell Cancer Vaccines Market Size (2018-2029)

9.2 Latin America Dendritic Cell Cancer Vaccines Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023)

9.4 Latin America Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Dendritic Cell Cancer Vaccines Market Size (2018-2029)

10.2 Middle East & Africa Dendritic Cell Cancer Vaccines Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023)

10.4 Middle East & Africa Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 3M Company

11.1.1 3M Company Company Detail

11.1.2 3M Company Business Overview

11.1.3 3M Company Dendritic Cell Cancer Vaccines Introduction

11.1.4 3M Company Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.1.5 3M Company Recent Development

11.2 Activarti

11.2.1 Activarti Company Detail

11.2.2 Activarti Business Overview

11.2.3 Activarti Dendritic Cell Cancer Vaccines Introduction

11.2.4 Activarti Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.2.5 Activarti Recent Development

11.3 Argos Therapeutics

11.3.1 Argos Therapeutics Company Detail

11.3.2 Argos Therapeutics Business Overview

11.3.3 Argos Therapeutics Dendritic Cell Cancer Vaccines Introduction

11.3.4 Argos Therapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.3.5 Argos Therapeutics Recent Development

11.4 Batavia Bioservices

11.4.1 Batavia Bioservices Company Detail

11.4.2 Batavia Bioservices Business Overview

11.4.3 Batavia Bioservices Dendritic Cell Cancer Vaccines Introduction

11.4.4 Batavia Bioservices Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.4.5 Batavia Bioservices Recent Development

11.5 Bellicum Pharmaceuticals

11.5.1 Bellicum Pharmaceuticals Company Detail

11.5.2 Bellicum Pharmaceuticals Business Overview

11.5.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Introduction

11.5.4 Bellicum Pharmaceuticals Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.5.5 Bellicum Pharmaceuticals Recent Development

11.6 Creagene

11.6.1 Creagene Company Detail

11.6.2 Creagene Business Overview

11.6.3 Creagene Dendritic Cell Cancer Vaccines Introduction

11.6.4 Creagene Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.6.5 Creagene Recent Development

11.7 DanDrit Biotech

11.7.1 DanDrit Biotech Company Detail

11.7.2 DanDrit Biotech Business Overview

11.7.3 DanDrit Biotech Dendritic Cell Cancer Vaccines Introduction

11.7.4 DanDrit Biotech Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.7.5 DanDrit Biotech Recent Development

11.8 DCPrime

11.8.1 DCPrime Company Detail

11.8.2 DCPrime Business Overview

11.8.3 DCPrime Dendritic Cell Cancer Vaccines Introduction

11.8.4 DCPrime Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.8.5 DCPrime Recent Development

11.9 Sanpower Corporation

11.9.1 Sanpower Corporation Company Detail

11.9.2 Sanpower Corporation Business Overview

11.9.3 Sanpower Corporation Dendritic Cell Cancer Vaccines Introduction

11.9.4 Sanpower Corporation Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.9.5 Sanpower Corporation Recent Development

11.10 Elios Therapeutics

11.10.1 Elios Therapeutics Company Detail

11.10.2 Elios Therapeutics Business Overview

11.10.3 Elios Therapeutics Dendritic Cell Cancer Vaccines Introduction

11.10.4 Elios Therapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.10.5 Elios Therapeutics Recent Development

11.11 ImmunoCellular Therapeutics

11.11.1 ImmunoCellular Therapeutics Company Detail

11.11.2 ImmunoCellular Therapeutics Business Overview

11.11.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Introduction

11.11.4 ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.11.5 ImmunoCellular Therapeutics Recent Development

11.12 Immunicum

11.12.1 Immunicum Company Detail

11.12.2 Immunicum Business Overview

11.12.3 Immunicum Dendritic Cell Cancer Vaccines Introduction

11.12.4 Immunicum Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.12.5 Immunicum Recent Development

11.13 Kiromic

11.13.1 Kiromic Company Detail

11.13.2 Kiromic Business Overview

11.13.3 Kiromic Dendritic Cell Cancer Vaccines Introduction

11.13.4 Kiromic Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.13.5 Kiromic Recent Development

11.14 Medigene

11.14.1 Medigene Company Detail

11.14.2 Medigene Business Overview

11.14.3 Medigene Dendritic Cell Cancer Vaccines Introduction

11.14.4 Medigene Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.14.5 Medigene Recent Development

11.15 Merck

11.15.1 Merck Company Detail

11.15.2 Merck Business Overview

11.15.3 Merck Dendritic Cell Cancer Vaccines Introduction

11.15.4 Merck Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.15.5 Merck Recent Development

11.16 Northwest Biotherapeutics

11.16.1 Northwest Biotherapeutics Company Detail

11.16.2 Northwest Biotherapeutics Business Overview

11.16.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Introduction

11.16.4 Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.16.5 Northwest Biotherapeutics Recent Development

11.17 Glaxo Smith Kline

11.17.1 Glaxo Smith Kline Company Detail

11.17.2 Glaxo Smith Kline Business Overview

11.17.3 Glaxo Smith Kline Dendritic Cell Cancer Vaccines Introduction

11.17.4 Glaxo Smith Kline Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.17.5 Glaxo Smith Kline Recent Development

11.18 Tellaorporation

11.18.1 Tellaorporation Company Detail

11.18.2 Tellaorporation Business Overview

11.18.3 Tellaorporation Dendritic Cell Cancer Vaccines Introduction

11.18.4 Tellaorporation Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.18.5 Tellaorporation Recent Development

11.19 Vaxil BioTherapeutics

11.19.1 Vaxil BioTherapeutics Company Detail

11.19.2 Vaxil BioTherapeutics Business Overview

11.19.3 Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Introduction

11.19.4 Vaxil BioTherapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023)

11.19.5 Vaxil BioTherapeutics Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Dendritic Cell Cancer Vaccines Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of CreaVax

    Table 3. Key Players of Sipuleucel-T (Provenge)

    Table 4. Key Players of Others

    Table 5. Global Dendritic Cell Cancer Vaccines Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Dendritic Cell Cancer Vaccines Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Dendritic Cell Cancer Vaccines Market Size by Region (2018-2023) & (US$ Million)

    Table 8. Global Dendritic Cell Cancer Vaccines Market Share by Region (2018-2023)

    Table 9. Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 10. Global Dendritic Cell Cancer Vaccines Market Share by Region (2024-2029)

    Table 11. Dendritic Cell Cancer Vaccines Market Trends

    Table 12. Dendritic Cell Cancer Vaccines Market Drivers

    Table 13. Dendritic Cell Cancer Vaccines Market Challenges

    Table 14. Dendritic Cell Cancer Vaccines Market Restraints

    Table 15. Global Dendritic Cell Cancer Vaccines Revenue by Players (2018-2023) & (US$ Million)

    Table 16. Global Dendritic Cell Cancer Vaccines Market Share by Players (2018-2023)

    Table 17. Global Top Dendritic Cell Cancer Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccines as of 2022)

    Table 18. Ranking of Global Top Dendritic Cell Cancer Vaccines Companies by Revenue (US$ Million) in 2022

    Table 19. Global 5 Largest Players Market Share by Dendritic Cell Cancer Vaccines Revenue (CR5 and HHI) & (2018-2023)

    Table 20. Key Players Headquarters and Area Served

    Table 21. Key Players Dendritic Cell Cancer Vaccines Product Solution and Service

    Table 22. Date of Enter into Dendritic Cell Cancer Vaccines Market

    Table 23. Mergers & Acquisitions, Expansion Plans

    Table 24. Global Dendritic Cell Cancer Vaccines Market Size by Type (2018-2023) & (US$ Million)

    Table 25. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2018-2023)

    Table 26. Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 27. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Type (2024-2029)

    Table 28. Global Dendritic Cell Cancer Vaccines Market Size by Application (2018-2023) & (US$ Million)

    Table 29. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2018-2023)

    Table 30. Global Dendritic Cell Cancer Vaccines Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 31. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2024-2029)

    Table 32. North America Dendritic Cell Cancer Vaccines Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 33. North America Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023) & (US$ Million)

    Table 34. North America Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029) & (US$ Million)

    Table 35. Europe Dendritic Cell Cancer Vaccines Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. Europe Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023) & (US$ Million)

    Table 37. Europe Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Asia-Pacific Dendritic Cell Cancer Vaccines Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Asia-Pacific Dendritic Cell Cancer Vaccines Market Size by Region (2018-2023) & (US$ Million)

    Table 40. Asia-Pacific Dendritic Cell Cancer Vaccines Market Size by Region (2024-2029) & (US$ Million)

    Table 41. Latin America Dendritic Cell Cancer Vaccines Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Latin America Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023) & (US$ Million)

    Table 43. Latin America Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029) & (US$ Million)

    Table 44. Middle East & Africa Dendritic Cell Cancer Vaccines Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Middle East & Africa Dendritic Cell Cancer Vaccines Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Middle East & Africa Dendritic Cell Cancer Vaccines Market Size by Country (2024-2029) & (US$ Million)

    Table 47. 3M Company Company Detail

    Table 48. 3M Company Business Overview

    Table 49. 3M Company Dendritic Cell Cancer Vaccines Product

    Table 50. 3M Company Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 51. 3M Company Recent Development

    Table 52. Activarti Company Detail

    Table 53. Activarti Business Overview

    Table 54. Activarti Dendritic Cell Cancer Vaccines Product

    Table 55. Activarti Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 56. Activarti Recent Development

    Table 57. Argos Therapeutics Company Detail

    Table 58. Argos Therapeutics Business Overview

    Table 59. Argos Therapeutics Dendritic Cell Cancer Vaccines Product

    Table 60. Argos Therapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 61. Argos Therapeutics Recent Development

    Table 62. Batavia Bioservices Company Detail

    Table 63. Batavia Bioservices Business Overview

    Table 64. Batavia Bioservices Dendritic Cell Cancer Vaccines Product

    Table 65. Batavia Bioservices Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 66. Batavia Bioservices Recent Development

    Table 67. Bellicum Pharmaceuticals Company Detail

    Table 68. Bellicum Pharmaceuticals Business Overview

    Table 69. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Product

    Table 70. Bellicum Pharmaceuticals Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 71. Bellicum Pharmaceuticals Recent Development

    Table 72. Creagene Company Detail

    Table 73. Creagene Business Overview

    Table 74. Creagene Dendritic Cell Cancer Vaccines Product

    Table 75. Creagene Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 76. Creagene Recent Development

    Table 77. DanDrit Biotech Company Detail

    Table 78. DanDrit Biotech Business Overview

    Table 79. DanDrit Biotech Dendritic Cell Cancer Vaccines Product

    Table 80. DanDrit Biotech Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 81. DanDrit Biotech Recent Development

    Table 82. DCPrime Company Detail

    Table 83. DCPrime Business Overview

    Table 84. DCPrime Dendritic Cell Cancer Vaccines Product

    Table 85. DCPrime Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 86. DCPrime Recent Development

    Table 87. Sanpower Corporation Company Detail

    Table 88. Sanpower Corporation Business Overview

    Table 89. Sanpower Corporation Dendritic Cell Cancer Vaccines Product

    Table 90. Sanpower Corporation Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 91. Sanpower Corporation Recent Development

    Table 92. Elios Therapeutics Company Detail

    Table 93. Elios Therapeutics Business Overview

    Table 94. Elios Therapeutics Dendritic Cell Cancer Vaccines Product

    Table 95. Elios Therapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 96. Elios Therapeutics Recent Development

    Table 97. ImmunoCellular Therapeutics Company Detail

    Table 98. ImmunoCellular Therapeutics Business Overview

    Table 99. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Product

    Table 100. ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 101. ImmunoCellular Therapeutics Recent Development

    Table 102. Immunicum Company Detail

    Table 103. Immunicum Business Overview

    Table 104. Immunicum Dendritic Cell Cancer Vaccines Product

    Table 105. Immunicum Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 106. Immunicum Recent Development

    Table 107. Kiromic Company Detail

    Table 108. Kiromic Business Overview

    Table 109. Kiromic Dendritic Cell Cancer Vaccines Product

    Table 110. Kiromic Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 111. Kiromic Recent Development

    Table 112. Medigene Company Detail

    Table 113. Medigene Business Overview

    Table 114. Medigene Dendritic Cell Cancer Vaccines Product

    Table 115. Medigene Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 116. Medigene Recent Development

    Table 117. Merck Company Detail

    Table 118. Merck Business Overview

    Table 119. Merck Dendritic Cell Cancer Vaccines Product

    Table 120. Merck Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 121. Merck Recent Development

    Table 122. Northwest Biotherapeutics Company Detail

    Table 123. Northwest Biotherapeutics Business Overview

    Table 124. Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Product

    Table 125. Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 126. Northwest Biotherapeutics Recent Development

    Table 127. Glaxo Smith Kline Company Detail

    Table 128. Glaxo Smith Kline Business Overview

    Table 129. Glaxo Smith Kline Dendritic Cell Cancer Vaccines Product

    Table 130. Glaxo Smith Kline Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 131. Glaxo Smith Kline Recent Development

    Table 132. Tellaorporation Company Detail

    Table 133. Tellaorporation Business Overview

    Table 134. Tellaorporation Dendritic Cell Cancer Vaccines Product

    Table 135. Tellaorporation Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 136. Tellaorporation Recent Development

    Table 137. Vaxil BioTherapeutics Company Detail

    Table 138. Vaxil BioTherapeutics Business Overview

    Table 139. Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Product

    Table 140. Vaxil BioTherapeutics Revenue in Dendritic Cell Cancer Vaccines Business (2018-2023) & (US$ Million)

    Table 141. Vaxil BioTherapeutics Recent Development

    Table 142. Research Programs/Design for This Report

    Table 143. Key Data Information from Secondary Sources

    Table 144. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Dendritic Cell Cancer Vaccines Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Dendritic Cell Cancer Vaccines Market Share by Type: 2022 VS 2029

    Figure 3. CreaVax Features

    Figure 4. Sipuleucel-T (Provenge) Features

    Figure 5. Others Features

    Figure 6. Global Dendritic Cell Cancer Vaccines Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Dendritic Cell Cancer Vaccines Market Share by Application: 2022 VS 2029

    Figure 8. Pediatrics Case Studies

    Figure 9. Adults Case Studies

    Figure 10. Dendritic Cell Cancer Vaccines Report Years Considered

    Figure 11. Global Dendritic Cell Cancer Vaccines Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 12. Global Dendritic Cell Cancer Vaccines Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 13. Global Dendritic Cell Cancer Vaccines Market Share by Region: 2022 VS 2029

    Figure 14. Global Dendritic Cell Cancer Vaccines Market Share by Players in 2022

    Figure 15. Global Top Dendritic Cell Cancer Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccines as of 2022)

    Figure 16. The Top 10 and 5 Players Market Share by Dendritic Cell Cancer Vaccines Revenue in 2022

    Figure 17. North America Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 18. North America Dendritic Cell Cancer Vaccines Market Share by Country (2018-2029)

    Figure 19. United States Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. Canada Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Europe Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Dendritic Cell Cancer Vaccines Market Share by Country (2018-2029)

    Figure 23. Germany Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. France Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. U.K. Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Italy Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Russia Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Nordic Countries Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Asia-Pacific Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Dendritic Cell Cancer Vaccines Market Share by Region (2018-2029)

    Figure 31. China Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Japan Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. South Korea Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Southeast Asia Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. India Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Australia Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Latin America Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Dendritic Cell Cancer Vaccines Market Share by Country (2018-2029)

    Figure 39. Mexico Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Brazil Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Middle East & Africa Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Dendritic Cell Cancer Vaccines Market Share by Country (2018-2029)

    Figure 43. Turkey Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Saudi Arabia Dendritic Cell Cancer Vaccines Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. 3M Company Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 46. Activarti Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 47. Argos Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 48. Batavia Bioservices Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 49. Bellicum Pharmaceuticals Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 50. Creagene Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 51. DanDrit Biotech Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 52. DCPrime Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 53. Sanpower Corporation Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 54. Elios Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 55. ImmunoCellular Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 56. Immunicum Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 57. Kiromic Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 58. Medigene Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 59. Merck Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 60. Northwest Biotherapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 61. Glaxo Smith Kline Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 62. Tellaorporation Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 63. Vaxil BioTherapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccines Business (2018-2023)

    Figure 64. Bottom-up and Top-down Approaches for This Report

    Figure 65. Data Triangulation

    Figure 66. Key Executives Interviewed